PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
Details for Australian Patent Application No. 2003256911 (hide)
International Classifications
Event Publications
6 November 2003 Complete Application Filed
Priority application(s): 60/399,518 30.07.02 US
25 March 2004 Application Open to Public Inspection
Published as AU-B-2003256911
10 July 2008 Application Accepted
Published as AU-B-2003256911
6 November 2008 Standard Patent Sealed
21 January 2010 Amendment Made
The nature of the amendment is: Amend patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003256912-TUMOR ASSOCIATED ANTIGEN, PEPTIDES THEREOF, AND USE OF SAME AS ANTI-TUMOR VACCINES
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser